12:41 PM
 | 
Jan 18, 2019
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Acceleron, Stemline price upsized follow-ons

Acceleron Pharma Inc. (NASDAQ:XLRN) and Stemline Therapeutics Inc. (NASDAQ:STML) have each priced upsized follow-ons, as one company prepares for key regulatory submissions and the other conducts its first product launch.

Acceleron said Jan. 16 that it raised $230 million through the sale of 5.3 million shares at $43. The price is a 7% discount to Acceleron's closing price of $46.44 on Jan. 14, when it proposed after market hours to raise $200 million. Its shares slipped $2.52 to $43.92 on...

Read the full 378 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >